Previous Seminars

2022-2023

Addressing the Suicide Dilemma: The Challenge of Measuring Outcomes (Stanley Edlavitch, PhD, MA, FACE)

Accelerated Approval: Implications for Speed, Efficacy, Safety, and Public Health (Diana Zuckerman, PhD)

Real-World Evidence Using Routinely Collected Health Data; When is the Evidence Convincing? (Rolf Groenwold, PhD)

Optimizing Antihypertensive Treatment in 2023 to Prevent Cardiovascular Disease and Dementia: Lessons Using Pharmacoepidemiology (Adam Bress, PharmD, MS)

What You Need to Know about the Inflation Reduction Act (Stacie Dusetzina, PhD)

Too Many Medicines – The What, Why, and How of Deprescribing Research (Michael Steinman, MD)

An Online Tool for Correcting Risk Ratio or Cumulative Incidence Estimates for Bias Due to Outcome Misclassification (Vinay Mehta, PhD, MS)

Enhancing the Evidence on the Effectiveness and Safety of Diabetes Medications (Elisabetta Patorno, MD, DrPH)

Useful Population Findings in Pediatric Psychopharmacology (Daniel Safer, MD)

2021-2022

Real-world Data and Regulatory Decision Making for Post-market Drug Safety: Hydrochlorothiazide Use and Risk of Non-melanoma Skin Cancer (Darren Toh, ScD) RECORDING

Pursuing Improved Drug Development and Use in CKD: Insights into Non-renal and Extracorporeal Clearance (Thomas D. Nolin, PharmD, PhD)

Determining the Comparative Benefits of New and Existing Drugs (Huseyin Naci, MHS, PhD) RECORDING

Administrative Claims Data Linked to Cancer Registry Data: Opportunities to Measure Comorbidity and its Impact on Cancer Patient Survival (Angela Mariotto, PhD) RECORDING

AI and Machine Learning in Healthcare: Challenges and Opportunities for Mitigating Bias and Promoting Fairness in Clinical Algorithms (Irene Dankwa-Mullan, MD, MPH)

Real-World Data, Advanced Analytics, and the Evolution of Postmarket Drug Safety Surveillance (Gerard Dal Pan, MD, MHS) RECORDING

Pharmaceutical Reimbursement Nuances and Quality Implications for the Supply Chain (Joey Mattingly, PhD, PharmD, MBA) RECORDING

Pregnancy Studies in the Context of FDA and EMA Guidance: Generating RWE for Assessing Pregnancy Safety (Sigal Kaplan, PhD)

Using mHealth to Measure Symptoms, Behavior, and Activity in Adolescents with Mood Disorders Treated with Antidepressants (Wendy Camelo Castillo, PhD) RECORDING

2020-2021

Are Generic Drugs as Effective and Safe as the Brand Names? Results from a Canadian Research Program (Jacinthe Leclerc, RN, PhD) RECORDING

Use of Real World Evidence in Regulatory Setting – Review of Strategy and Methodological Challenges (Douglas Kou, PhD, MPH, MA) RECORDING

FDA’s Sentinel System: An Overview of the FDA’s Active Surveillance System for Medical Product Safety and Effectiveness (Sarah Dutcher, PhD, MS) RECORDING

Use of Psychiatric Drugs in Nursing Homes: Impact of the COVID Pandemic (James Goodwin, MD) RECORDING

Digital Therapeutics in Psychiatry: Novel Possibilities and New Considerations (Sunny Tang, MD) RECORDING

Assessing the External Validity of Trial Results: Applications in Oncology (Jennifer Lund, PhD) RECORDING

Mortality Risk of Antipsychotic Augmentation for Adult Depression: Context and Methodological Considerations (Tobias Gerhard, BSPharm, PhD) RECORDING